THU0261 Outcomes in Systemic Lupus Erythematous (SLE) Patients with High Disease Activity Treated with Belimumab: Results from an Observational Study in the United States (U.S.)

H Kan,R Pappu,C Collins,M Dall’Era,V Koscielny,C Molta,M B Mcguire

doi:10.1136/annrheumdis-2013-eular.789

THU0261 Outcomes in Systemic Lupus Erythematous (SLE) Patients with High Disease Activity Treated with Belimumab: Results from an Observational Study in the United States (U.S.)

H Kan, R Pappu + Show 5 more

https://doi.org/10.1136/annrheumdis-2013-eular.789

Copy DOI

Export

Save

Cite

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2013

Affiliation: Research Triangle Park Foundation, GlaxoSmithKline (United States), MedStar Washington Hospital Center, University of California, San Francisco, GlaxoSmithKline (United Kingdom)

#Systemic Lupus Erythematous Patients #Systemic Lupus Erythematous #Index Date #Clinical Practice Settings #High Disease Activity #Reduction In Steroid Dose #Eligible Patient Charts #Years Of Practice Experience #Key Patient Characteristics #Oral Steroid Dose

Abstract
Full-Text
Similar Papers

Abstract

Listen

BackgroundPost hoc analyses of belimumab BLISS trials identified baseline factors generally associated with high disease activity as predictors of improved response to treatment, such as SELENA-SLEDAI (SS)> 10, low complement...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

THU0261 Outcomes in Systemic Lupus Erythematous (SLE) Patients with High Disease Activity Treated with Belimumab: Results from an Observational Study in the United States (U.S.)